Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data
Erik Volz, Swapnil Mishra, Meera Chand, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 649

Showing 1-25 of 649 citing articles:

SARS-CoV-2 variants, spike mutations and immune escape
William T. Harvey, Alessandro M. Carabelli, Ben Jackson, et al.
Nature Reviews Microbiology (2021) Vol. 19, Iss. 7, pp. 409-424
Open Access | Times Cited: 3370
Detection of a SARS-CoV-2 variant of concern in South Africa
Houriiyah Tegally, Eduan Wilkinson, Marta Giovanetti, et al.
Nature (2021) Vol. 592, Iss. 7854, pp. 438-443
Open Access | Times Cited: 1674
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Shabir A. Madhi, Vicky L. Baillie, Clare Cutland, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 20, pp. 1885-1898
Open Access | Times Cited: 1270
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
Robert Challen, Ellen Brooks‐Pollock, Jonathan M. Read, et al.
BMJ (2021), pp. n579-n579
Open Access | Times Cited: 831
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Dami A. Collier, Anna De Marco, Isabella A. T. M. Ferreira, et al.
Nature (2021) Vol. 593, Iss. 7857, pp. 136-141
Open Access | Times Cited: 692
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)
Victoria Hall, Sarah Foulkes, André Charlett, et al.
The Lancet (2021) Vol. 397, Iss. 10283, pp. 1459-1469
Open Access | Times Cited: 649
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
Vivek Shinde, Sutika Bhikha, Zaheer Hoosain, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 20, pp. 1899-1909
Open Access | Times Cited: 631
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley, et al.
The Lancet (2021) Vol. 397, Iss. 10282, pp. 1351-1362
Open Access | Times Cited: 624
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Emma C. Thomson, Laura E. Rosen, James G. Shepherd, et al.
Cell (2021) Vol. 184, Iss. 5, pp. 1171-1187.e20
Open Access | Times Cited: 623
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Leonidas Stamatatos, Julie Czartoski, Yu-Hsin Wan, et al.
Science (2021) Vol. 372, Iss. 6549, pp. 1413-1418
Open Access | Times Cited: 573
SARS-CoV-2 variants and ending the COVID-19 pandemic
Arnaud Fontanet, Brigitte Autran, Bruno Lina, et al.
The Lancet (2021) Vol. 397, Iss. 10278, pp. 952-954
Open Access | Times Cited: 556
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Alexander Muik, Ann-Kathrin Wallisch, Bianca Sänger, et al.
Science (2021) Vol. 371, Iss. 6534, pp. 1152-1153
Open Access | Times Cited: 542
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Xianding Deng, Miguel Garcia-Knight, Mir M. Khalid, et al.
Cell (2021) Vol. 184, Iss. 13, pp. 3426-3437.e8
Open Access | Times Cited: 513
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
Kaichun Wu, Anne P. Werner, Juan I. Moliva, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 473
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 397, Iss. 10289, pp. 2049-2059
Open Access | Times Cited: 471
A guideline to limit indoor airborne transmission of COVID-19
Martin Z. Bazant, John W. M. Bush
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 17
Open Access | Times Cited: 421
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7
Bo Meng, Steven A. Kemp, Guido Papa, et al.
Cell Reports (2021) Vol. 35, Iss. 13, pp. 109292-109292
Open Access | Times Cited: 412
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Xiaoying Shen, Haili Tang, Charlene McDanal, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 4, pp. 529-539.e3
Open Access | Times Cited: 377
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution
Jiří Zahradník, Shir Marciano, Maya Shemesh, et al.
Nature Microbiology (2021) Vol. 6, Iss. 9, pp. 1188-1198
Open Access | Times Cited: 377
SARS-CoV-2 within-host diversity and transmission
Katrina Lythgoe, Matthew Hall, Luca Ferretti, et al.
Science (2021) Vol. 372, Iss. 6539
Open Access | Times Cited: 369
Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States
Nicole L. Washington, Karthik Gangavarapu, Mark Zeller, et al.
Cell (2021) Vol. 184, Iss. 10, pp. 2587-2594.e7
Open Access | Times Cited: 356
The variant gambit: COVID-19’s next move
Jessica A. Plante, Brooke Mitchell, Kenneth S. Plante, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 4, pp. 508-515
Open Access | Times Cited: 343
Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics
Michael I. Barton, Stuart A. MacGowan, Mikhail A. Kutuzov, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 333
Age groups that sustain resurging COVID-19 epidemics in the United States
Mélodie Monod, Alexandra Blenkinsop, Xiaoyue Xi, et al.
Science (2021) Vol. 371, Iss. 6536
Open Access | Times Cited: 325
Page 1 - Next Page

Scroll to top